bebtelovimab   Click here for help

GtoPdb Ligand ID: 11921

Synonyms: LY-3853113 | LY-CoV-1404 | LY-CoV1404 | LY3853113
Compound class: Antibody
Comment: Bebtelovimab (LY3853113) is a SARS-CoV-2-neutralising monoclonal antibody that binds to the virus' spike surface glycoprotein [2]. It was reported to be effective against the delta and early omicron variants (B.1.617.2 and B.1.1.529 respectively). As of July 2022 bebtelovimab was the only available mAb to show preserved in vitro activity against the omicron BA.4 and BA.5 subvariants that were superceding previous omicron subvariants at that time [1].
Click here for help
References
1. Hentzien M, Autran B, Piroth L, Yazdanpanah Y, Calmy A. (2022)
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab.
Lancet Infect Dis, [Epub ahead of print]. DOI: 10.1016/S1473-3099(22)00495-9 [PMID:35863364]
2. Westendorf K, Wang L, ┼Żentelis S, Foster D, Vaillancourt P, Wiggin M, Lovett E, van der Lee R, Hendle J, Pustilnik A et al.. (2022)
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
bioRxiv, Preprint. DOI: 10.1101/2021.04.30.442182 [PMID:33972947]